tbuckley/cabot-search huggingface dataset:
Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations
Authors: Mazepa A. Marshall, Michael Evans, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan R Woods, Ara Metjian, Kristin Bagby, Yara Park, Jay S Raval, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K Liles, Susan Eubanks, Frank Akwaa, Lisa Baumann Kreuziger, J. Evan Sadler, Meera Sridharan, Ronald S. Go, Keith R McCrae, Shruti Chaturvedi, Harsh Vardhan Upreti, Rahil Kohli, Ming Y. Lim, X. Long Zheng, Nicole K. Kocher, Radhika Gangaraju, Spero Cataland
Journal: Blood (2019)
Resting electrocardiographic variables of patients with severe coronary artery disease undergoing coronary artery bypass graft surgery plus intramyocardial bone marrow cell injection: an one-year follow up study
Authors: Márcio Sommer Bittencourt, I T Schettert, C J Grupi, L A M Cesar, J E Krieger, L A O Dallan, S A Oliveira, L H W Gowdak
Journal: Circulation (2008)
Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence
Authors: Caleb Ho, Mustafa Syed, Wayne Yu, Kseniya Petrova-Drus, Jin Juan Yao, Christine Moung, Jason Chang, Jamal Benhamida, Chad Vanderbilt, Mikhail Roshal, Qi Gao, Lidia Maciag, Meiyi Wang, Yuanyuan Ma, Even H Rustad, Ying Huang, Kasey Hutt, Jeffrey E Miller, Ola Landgren, Khedoudja Nafa, Maria E Arcila
Journal: Blood (2019)
Vaccine Response to a Neo Polyssacharide Antigen Typhim Vi on the Identification of Secondary Immunodeficiencies in Hematological Malignancy
Authors: Juliana Ochoa-Grullón, Celina Benavente Cuesta, G Cordero Torres, Cristina Pérez López, Ascensión Peña Cortijo, Antonia Rodríguez de la Peña, Ana Álvarez Carmona, Marta Mateo Morales, Edgard Rodríguez de Frías, Kissy Guevara-Hoyer, Miguel Fernández-Arquero, Lidia Fernández-Paredes, Rebeca Perez de Diego, Silvia Sánchez-Ramón
Journal: Blood (2019)
Biocompatible Microrobots: Magnetically Actuated SiCN‐Based Ceramic Microrobot for Guided Cell Delivery (Adv. Healthcare Mater. 21/2019)
Authors: Ki‐Won Gyak, Sungwoong Jeon, Laura Ha, Sangwon Kim, Jin‐young Kim, Kwang‐Sup Lee, Hongsoo Choi, Dong‐Pyo Kim
Journal: Advanced Healthcare Materials (2019)

In article number 1900739 by Hongsoo Choi, Dong-Pyo Kim, and co-workers, biocompatible ceramic microrobots are developed for cell delivery for the first time. The microrobots are fabricated by 3D laser lithography, and magnetic nanoparticles are immobilized on the surface of the microrobots to manipulate the movement of the microrobots by an external magnetic field.
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab
Authors: Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, John P. Leonard, Izidore S. Lossos, Christopher R. Flowers, Grerk Sutamtewagul, Jonathon B. Cohen, Derick R. Peterson, Loretta J. Nastoupil
Journal: Blood (2019)
Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses
Authors: Teppei Sakoda, Yoshikane Kikushige, Takuya Harada, Hidetoshi Irifune, Masayasu Hayashi, Goichi Yoshimoto, Toshihiro Miyamoto, Koichi Akashi
Journal: Blood (2019)
New physical signs associated with severe aortic regurgitation are still being described
Authors: Keith Buchan, Sayed Abdulmotaleb Almoosawy, Stephen Cross
Journal: BMJ (2019)

Minerva mentions de Musset’s sign of aortic incompetence and its earlier recognition by William Withering.1

In severe acute aortic regurgitation, most commonly due to aortic valve endocarditis, a form of extreme diastolic ventricular interaction …
Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma
Authors: Mohamed Rizk, Ola Rizq, Motohiko Oshima, Yaeko Nakajima-Takagi, Shuhei Koide, Atsunori Saraya, Yusuke Isshiki, Tetsuhiro Chiba, Satoshi Yamazaki, Anqi Ma, Jian Jin, Atsushi Iwama, Naoya Mimura
Journal: Blood (2019)
Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study
Authors: Farrukh Shah, Paul Telfer, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, Joe Hickey, Clark Paramore, Minesh Jobanputra, Kate Ryan
Journal: Blood (2019)
The Diseases of Warm Countries. A Handbook for Medical Men.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
STEM-03. CONSUMPTION OF A HIGH-FAT DIET INHIBITS THE TUMOR SUPPRESSIVE ACTIVITY OF HYDROGEN SULFIDE, DRIVING CANCER STEM CELL ENRICHMENT AND DISEASE AGGRESSION IN GLIOBLASTOMA
Authors: Daniel Silver, Gustavo Roversi, Nazmin Bithi, Katie Troike, Chase Neumann, J Mark Brown, Christopher Hine, Justin Lathia
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) remains among the deadliest of human malignancies. Effective disease management is lacking due in part to the emergence of the cancer stem cell (CSC) phenotype. The tumor cell extrinsic, environmental, and lifestyle factors that result in CSC enrichment are not well understood. Alongside other pathological features, the CSC state endows populations of tumor cells with a fluid metabolic profile that enables utilization of multiple nutrition sources. Therefore, to test the impact of diet on CSC enrichment, we interrogated disease progression in tumor-bearing mice fed either a high-fat diet (HFD), similar to the Western Pattern diet or a control low-fat diet. Compared to controls, HFD-consumption resulted in the presentation of a hyper-aggressive disease phenotype with truncated survival and tumors markedly enriched in tumor-initiating SOX2+ CSCs. To understand the underlying mechanism driving this finding, we examined tumors for the diet-regulated metabolite hydrogen sulfide (H2S). H2S is an endogenously produced bio-active gasotransmitter similar to nitric oxide. It functions principally through protein S-sulfhydration to regulate a variety of cellular programs including mitochondrial function, stress signaling and metabolism. While there is exceedingly limited information on H2S and GBM, its HFD-driven suppression has been reported in other organ systems. We discovered a significant reduction in H2S synthesis resulting from HFD-consumption in the brain of the mouse and a striking decrease in protein S-sulfhydration in human GBM tumor tissue when compared to non-cancerous control brain tissue. We demonstrated that chemical inhibition of H2S synthesis resulted in increased tumor cell viability whereas exposure to chemical H2S donors led to pronounced cell death of cultured mouse and human GBM cells. These data demonstrate for the first time, that H2S serves as a tumor suppressor for GBM. Moreover, the diet-driven suppression of H2S helps explain the hyper-aggressive in vivo phenotype that presents in response to HFD-consumption.
Association of a P2Y<sub>12</sub> Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications
Authors: Alexander C. Fanaroff, Eric D. Peterson, Lisa A. Kaltenbach, Christopher P. Cannon, Niteesh K. Choudhry, Timothy D. Henry, Kevin J. Anstrom, David J. Cohen, Eileen Fonseca, Naeem D. Khan, Gregg C. Fonarow, Tracy Y. Wang
Journal: JAMA Cardiology (2019)

The Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) cluster-randomized trial found that copayment reduction for P2Y12 inhibitors improved 1-year patient persistence in taking that medication.To assess whether providing copayment reduction for P2Y12 inhibitors increases patient persistence in taking other secondary prevention cardiovascular medications.This post hoc analysis of the ARTEMIS trial includes data from 287 hospitals that enrolled patients between June 2015 and September 2016. Patients hospitalized with acute myocardial infarction were included. Data analysis occurred from May 2018 through August 2019.Hospitals randomized to the intervention provided patients vouchers that waived copayments for P2Y12 inhibitors fills for 1 year. Hospitals randomized to usual care did not provide study vouchers.Persistence in taking β-blocker, statin, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker medications at 1 year, defined as the absence of a gap in medication supply of 30 or more days by pharmacy fill data in the intervention-arm (intent-to-treat) population.A total of 131 hospitals (with 5109 patients) were randomized to the intervention, and 156 hospitals (with 3264 patients) randomized to the control group. Patients discharged from intervention hospitals had higher persistence in taking statins (2247 [46.1%] vs 1300 [41.9%]; adjusted odds ratio, 1.11 [95% CI, 1.00-1.24]), and β-blockers (2235 [47.6%] vs 1277 [42.5%]; odds ratio, 1.23 [95% CI, 1.10-1.38]), although the association was smaller than that seen for P2Y12 inhibitors (odds ratio, 1.47 [95% CI, 1.29-1.66]). Persistence in taking angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers were also numerically higher among patients in the intervention arm than in the usual-care arm, but this was not significant after risk adjustment (1520 [43.9%] vs 847 [40.5%]; adjusted odds ratio, 1.10 [95% CI, 0.97-1.24]). Patients in the intervention arm reported greater financial burden associated with medication cost than the patients in the usual-care arm at baseline, but these differences were no longer significant at 1 year.Reducing patient copayments for 1 medication class increased persistence not only to that therapy class but may also have modestly increased persistence to other post-myocardial infarction secondary prevention medications. These findings have important implications for the clinical utility and cost-effectiveness of medication cost-assistance programs.ClinicalTrials.gov identifier: NCT02406677.
Eliminating Cervical Cancer
Authors: R. A. McInroy
Journal: BMJ (1964)

Eliminating Cervical Cancer SIR,-In your leading article (5 December, p. 1409) you stress the need for a comprehen- sive programme to screen symptomless women for carcinoma of the cervix uteri.Part of such a programme is the investigation of possible alternatives to cytology.Two years ago Bonham and Gibbs' re- ported excellent results using the biochemical estimation of 6-phosphogluconate-dehydrogenase activity in vaginal fluid as a screening test.Comparing this enzyme assay with cytology in an extensive trial, we too have been impressed by the consistently raised 6- phosphogluconate dehydrogenase activity in the presence of early invasive carcinoma of both cervix and corpus uteri.However, there are several serious limitations to the use of this technique as a screening test at present.The first of these is that only half of the patients with carcinoma in situ have raised 6-phosphogluconate-dehydrogenase activity.The second is that the incidence of falsepositive reactors, women with raised enzyme activity but no clinical or cytological evidence of malignancy, is high particularly in the post-menopausal group.Thirdly, no way has yet been found to preserve the activity of the enzyme long enough for the convenient cen- tralization of samples for analysis.If these limitations can be overcome, and we think there is a reasonable chance that they can be, such a biochemical assay would be very welcome, as it lends itself readily to automation.We envisage its place being that of a first screening test.Samples would be taken concurrently for both enzyme analysis and for cytology, but only in those cases with a positive enzyme test would the smears need to be examined cytologically.-Weare, etc.,
Effect of the Unfolded Protein Response and Oxidative Stress on Mutagenesis of CSF3R a Model of Evolution of Severe Congenital Neutropenia to Myelodysplastic Syndrome/Acute Myeloid Leukemia
Authors: Adya Sapra, Roman Jaksik, Sara Biesiadny, Hrishikesh M Mehta, Marek Kimmel, Seth J. Corey
Journal: Blood (2019)
Advancing Healthcare Outcomes for Sickle Cell Disease in Nigeria Using Mobile Health Tools
Authors: Arwa Fraiwan, Muhammad Noman Hasan, Ran An, Amy J. Rezac, Nicholas J. Kocmich, Tolulope Oginni, Grace Mfon Olanipekun, Fatimah Hassan-Hanga, Binta W. Jibir, Safiya Gambo, Priyaleela Thota, Stephen K. Obaro, Umut A. Gurkan
Journal: Blood (2019)
Evaluating serum periostin levels in allergic bronchopulmonary aspergillosis
Authors: Jun Tanaka, Akira Hebisawa, Tsuyoshi Oguma, Katsuyoshi Tomomatsu, Junko Suzuki, Hiroshige Shimizu, Yoshinori Kawabata, Takashi Ishiguro, Noboru Takayanagi, Soichiro Ueda, Koichi Fukunaga, Masami Taniguchi, Junya Ono, Shoichiro Ohta, Kenji Izuhara, Koichiro Asano
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Defective Autophagy in MPN Were Predominantly Detected in Megakaryocytes in Philadelphia Negative (Ph -) Myeloproliferative Neoplasm
Authors: Jen-Chin Wang, Guanfang Shi, Karan Josan, Preethi Ramachandran, Vladimir Gotlieb, Gardith Joseph, Sherif A. Nasr
Journal: Blood (2019)
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Authors: Alfred L. Garfall, Adam D. Cohen, Simon F Lacey, Lifeng Tian, Wei-Ting Hwang, Dan T. Vogl, Adam Waxman, Eric Lancaster, Anne Marie Nelson, Regina Ferthio, Andrew Fesnak, Anne Lamontagne, Andrea Brennan, Jamie Guilliams, Whitney Lynn Gladney, J. Joseph Melenhorst, Regina M Young, Don L. Siegel, Bruce L Levine, Jennifer Brogdon, Randi E. Isaacs, Carl H June, Michael C. Milone, Edward A. Stadtmauer
Journal: Blood (2019)
OC-065 Pouch polyps in fap – a clinical problem or an endoscopic curiosity?
Authors: NR O’Shea, NC Hodges, RF Man, SK Clark, ACVon Roon, AR Latchford
Journal: Gut (2017)

Introduction  Restorative proctocolectomy (RPC) is one of the surgical options for patients with Familial Adenomatous Polyposis (FAP). Current guidelines suggest annual endoscopic pouch surveillance as formation of adenomas and carcinomas have been reported, however the data are few and the clinical impact of these not well established.  Method  We identified all FAP patients with a pouch undergoing surveillance at our institution, and retrospectively analysed our prospectively maintained polyposis database. Demographic data, details of surgery, original histopathology and follow-up pouch endoscopy reports and pathology findings were obtained.  Results  We identified 388 patients with FAP who had undergone pouch surgery from 1978 to May 2016; 260 had endoscopic follow-up at our institution. 131 (50%) were male. At the time of analysis, the median age was 47 years (range 7–85), and median pouch age was 15 years (range   Adenomatous polyps were found in 77% (200) of the ileoanal pouches. 53% (138) had cuff and 64% (166) had ileal pouch body adenomas. The time to first polyp formation was not significantly different between cuff (median 6, range 1–30 years) and pouch body (median 6, range 1–24 years), p=0.11. Pouch body adenomas developed in 47% (49/104) at 10 years and 65% (36/55) by 20 years. Cuff polyps were seen in 24% (25/104) and 27% (15/55) at 10 and 20 years respectively. The polyp count range per patient was 1–50 and 1–500 for cuff and pouch body polyps respectively.  12% (30) of cuff polyps and 5% (12) of pouch body polyps were >1 cm in size; range 10–60 mm (median 20 mm) in the cuff and 15–40 mm (median 25 mm) in the pouch body. 82% of the polyps>1 cm were treated with 1–7 (median 1) endoscopic mucosal resections. 14 patients (5%) required at least one examination under general anaesthesia for assessment and polyp resection. Pouchectomy was performed in 3% (7) for endoscopically unmanageable polyps.  High grade dysplasia/adenocarcinoma was identified in 3 cuff polyps at 4, 13 and 17 years following pouch formation. Pouchectomy was performed in all 3 cases. No pouch body cancers were identified.  Conclusion  Adenomatous polyps are common in the cuff and pouch body following RPC in FAP patients. The risk of cuff and pouch body polyps increases with pouch age. Large pouch polyps often require recurrent endoscopic intervention and surgery is indicated if endoscopic removal is not feasible. High quality endoscopic surveillance is mandated.  Disclosure of Interest  None Declared
SURG-11. PATTERNS OF RECURRENCES OF OLFACTORY NEUROBLASTOMA AFTER SURGICAL RESECTION
Authors: Jong Hee Chang, Ju Hyung Moon, Eui Hyun Kim, Kyu Sung Lee, Chang-Ok Suh
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Patterns of failure in patients with olfactory neuroblastoma (ONB) according to two surgical approaches, craniofacial resection (CFR) and endoscopic surgery (ENDO), have yet to be analyzed. METHODS We retrospectively reviewed 30 patients with surgically treated ONB between January 1995 and October 2018. Sixteen (53.3%) patients underwent CFR (9 CFR alone, 7 ENDO-assisted CFR) and 14 (46.7%) underwent ENDO. Twenty-one (70.0%) patients underwent post-operative radiotherapy (RT). RESULTS At a median follow-up of 53.8 months (range 10.4–195.3), the 5-year progression-free survival (PFS) and 10-year overall survival were 37.3% and 57.5%, respectively. Patients with adjuvant RT had a 5-year PFS of 46.7%, whereas those treated with surgery alone had a 5-year PFS of 19.4% (p = 0.01). Locoregional failure (LRF) occurred in ten patients (median 59.6 months after initial diagnosis; range 12.7–59.7). Neck node metastasis occurred in 23.3% (7 of 30). Five patients with ENDO showed LRF and underwent proper subsequent treatments with either surgery or adjuvant RT. Approximately 31.3% patients (five patients) in the CFR group experienced distant metastasis in the intracranial dura region (median 116.4 months after initial diagnosis; range 2.6–142.4). Three of four patients who developed LRF after CFR developed dura-based metastasis. CONCLUSIONS Both dura-based and neck node metastasis in the delayed phase were distinct patterns of failure in ONB. Patterns of recurrence differed based on surgical approach; dura-based metastases were common after CFR. LRF was the distinct failure pattern in ENDO, but could be successfully salvaged. Treatment outcome was improved considerably with RT following surgical resection.
GENE-45. DISSECTING THE DRIVERS OF ADULT H3K27M-GLIOMAS AT THE SINGLE-CELL LEVEL
Authors: Ilon Liu, Byron Avihai, Johannes Gojo, Keith Ligon, Thomas Czech, Irene Slavc, Claudia Kleinman, Nada Jabado, Mariella Filbin
Journal: Neuro-Oncology (2019)

Abstract Diffuse midline gliomas are characterized by a lysine27-to-methionine mutation in histone H3 (H3K27M-glioma) and represent a highly aggressive molecular entity of high-grade gliomas. These mutations have primarily been described in children, but are also increasingly recognized in adults. In pediatric H3K27M-gliomas, the transcriptional architecture and cellular composition have been studied at the single-cell level. Data suggest that these tumors arise through malignant transformation of a glial progenitor during a specific neurodevelopmental time window. On the other hand, little is known about the architecture and cellular context of adult H3K27M-gliomas, and it remains to be elucidated whether they are driven by the same or by distinct oncogenic programs as their pediatric counterparts. Here, we utilize single-cell transcriptomics to characterize the transcriptional landscape of five H3K27M-gliomas from adult patients aged 22 to 56 years (median 33 years). We describe the specific cellular and microenvironmental architecture of the adult tumors, which comprises distinct populations of cancer and normal cells. We contrast our findings to 12 location-matched pediatric H3K27M-tumors from patients aged 2.5 to 15 years (median 8 years) to identify features related to tumorigenesis and developmental context in light of the shared hallmark H3K27M mutation. Our preliminary data indicate shared gene expression programs between adult and pediatric tumors. However, we find significant differences in the composition of the immune compartment as well as less pronounced differentiation programs in the adult tumors. Our findings provide an unprecedented insight into the composition of adult H3K27M-gliomas and advance our understanding of this molecular tumor class.
Abstract 16998: Overuse of Cardiac Stress Testing in Asymptomatic Patients Results From a National Database
Authors: Mohammed Ruzieh, John Mandrola, Gerald V Naccarelli, Andrew J Foy
Journal: Circulation (2018)

Background: Cardiac stress testing is indicated in patients with symptoms suggestive of ischemic heart disease. Nonetheless, asymptomatic patients frequently undergo stress testing for screening purpose. Objective: To assess the frequency of stress testing use among asymptomatic patients. Methodology: We used the Truven MarketScan database to identify our cohort. We screened patients who had an outpatient stress testing between 2006 - 2014. Patients who had an emergency department visit or a hospital admission within a month before the stress test, or those who had surgery within a month after the stress test, were excluded from the study. Patients were considered asymptomatic if they didn’t have a diagnosis code of chest pain, angina, shortness of breath or palpitations in the three months before the stress test. Data from the baseline period, which started a year before the index date and ended on the index date, were used to obtain baseline characteristics and comorbidities. Data identified using [ICD-9-CM] diagnoses codes. Results: A total of 5,430,008 stress tests included in the final data analyses. The number of stress tests in asymptomatic patients was 1,822,817 (34%). Since 2006, there has been a decrease in the number of stress tests performed in asymptomatic patients. However, this remained high at 31% in 2014, figure1. Mean age was similar between patients who had symptoms-related and asymptomatic stress tests (53 ± 8 vs. 55 ± 7). However, compared to symptoms-related stress tests, patients with asymptomatic stress testing were more likely to be men (50% vs. 67%), and were more likely to have DM (21% vs. 26%), hypertension (50% vs. 56%), and history of CAD (53% vs. 61%), respectively. Conclusion: Significant number of stress tests are performed in asymptomatic patients. Although, this has decrease over time, educational efforts should continue to target overuse of stress tests. &lt;!--EndFragment--&gt;
P1.24 Endobronchial Ultrasound plus Fine Needle Aspiration (EBUS-TBNA) in Lesions Simulating Pulmonary Neoplasm: Pulmonary Myospherulosis
Authors: L. Fernandez-Trujillo, S. Sanchez, E.I. Morales, L. Sua, M. Velasquez
Journal: Journal of Thoracic Oncology (2019)